Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Practice
Open Access

Extended-release monthly buprenorphine injection

Ari B. Cuperfain, Tianna Costa and Nitin Chopra
CMAJ January 09, 2023 195 (1) E14; DOI: https://doi.org/10.1503/cmaj.220730
Ari B. Cuperfain
Department of Psychiatry (Cuperfain, Chopra) and Centre for Addiction and Mental Health (Costa, Chopra), University of Toronto, Toronto, Ont.
MD MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tianna Costa
Department of Psychiatry (Cuperfain, Chopra) and Centre for Addiction and Mental Health (Costa, Chopra), University of Toronto, Toronto, Ont.
RPh PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nitin Chopra
Department of Psychiatry (Cuperfain, Chopra) and Centre for Addiction and Mental Health (Costa, Chopra), University of Toronto, Toronto, Ont.
MD DABPN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Extended-release buprenorphine (BUP-XR) is a subcutaneous monthly depot injection used to treat opioid use disorder

In 2018, Health Canada approved the only BUP-XR treatment available in Canada, under the brand name Sublocade. It is covered by all provinces and territories as part of their public drug plans, primarily for treating moderate-to-severe opioid use disorder. All prescribers across Canada must complete online training, which is required by Health Canada.

Patients should be stabilized on sublingual buprenorphine before BUP-XR is initiated

Patients can receive BUP-XR if they are stabilized on 8–24 mg of sublingual buprenorphine for at least 7 days. They can then receive BUP-XR 300 mg monthly for the first 2 months, followed by 100 mg monthly as maintenance. Therapeutic effect first occurs within 24 hours.1 Specialist consultation is suggested for patients who require greater expediency. Given the reduced risk of diversion or misuse, BUP-XR does not need to be combined with naloxone.2

For maintaining abstinence from illicit opioids, BUP-XR has been shown to be superior to placebo

A randomized, double-blind, placebo-controlled trial showed mean abstinence rates were 42.7% for participants taking BUP-XR, compared with 5.0% for placebo over a 24-week study period.1 BUP-XR has also been associated with higher treatment satisfaction, lower treatment burden and greater convenience than sublingual buprenorphine, with the main adverse effect reported being injection-site irritation.3

Safe and effective use of BUP-XR depends on patient factors

BUP-XR can be recommended for patients with challenges adhering to daily-dosing treatments.4 A comparative effectiveness study showed that people who were incarcerated and maintained on BUP-XR had greater treatment retention after release from incarceration than with sublingual buprenorphine.5 For patients who anticipate becoming or are pregnant, BUP-XR should be used with caution, owing to teratogenicity risk shown in animal models. As yet, BUP-XR has not been studied in the management of chronic pain.

Psychosocial support remains a crucial aspect of treatment

Patients receiving BUP-XR benefit from regular contact with health care providers and should be offered interventions that reinforce harm reduction and engagement, such as addiction counselling, peer support, contingency management, affordable housing and income support.6

Footnotes

  • Competing interests: Ari Cuperfain reports receiving the American Association of Addiction Psychiatry John Renner Award. No other competing interests were declared.

  • This article has been peer reviewed.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    1. Haight BR,
    2. Learned SM,
    3. Laffont CM,
    4. et al.
    RB-US-13-0001 2Study Investigators. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393:778–90.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Ling W,
    2. Shoptaw S,
    3. Goodman-Meza D
    . Depot buprenorphine injection in the management of opioid use disorder: from development to implementation. Subst Abuse Rehabil 2019; 10:69–78.
    OpenUrl
  3. ↵
    1. Lintzeris N,
    2. Dunlop AJ,
    3. Haber PS,
    4. et al
    . Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial. JAMA Netw Open 2021; 4:e219041.
    OpenUrl
  4. ↵
    1. Peckham AM,
    2. Kehoe LG,
    3. Gray JR,
    4. et al
    . Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: a retrospective case series. J Subst Abuse Treat 2021;126:108316.
    OpenUrl
  5. ↵
    1. Lee JD,
    2. Malone M,
    3. McDonald R,
    4. et al
    . Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail. JAMA Netw Open 2021;4:e2123032.
    OpenUrl
  6. ↵
    1. George TP,
    2. Welsh L,
    3. Franchuk SL,
    4. et al
    . Why integrating medications and psychosocial interventions is important to successfully address the opioid crisis in Canada. Can J Psychiatry 2022;67:176–8.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 195 (1)
CMAJ
Vol. 195, Issue 1
9 Jan 2023
  • Table of Contents
  • Index by author
  • Podcast

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Extended-release monthly buprenorphine injection
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Extended-release monthly buprenorphine injection
Ari B. Cuperfain, Tianna Costa, Nitin Chopra
CMAJ Jan 2023, 195 (1) E14; DOI: 10.1503/cmaj.220730

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Extended-release monthly buprenorphine injection
Ari B. Cuperfain, Tianna Costa, Nitin Chopra
CMAJ Jan 2023, 195 (1) E14; DOI: 10.1503/cmaj.220730
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Extended-release buprenorphine (BUP-XR) is a subcutaneous monthly depot injection used to treat opioid use disorder
    • Patients should be stabilized on sublingual buprenorphine before BUP-XR is initiated
    • For maintaining abstinence from illicit opioids, BUP-XR has been shown to be superior to placebo
    • Safe and effective use of BUP-XR depends on patient factors
    • Psychosocial support remains a crucial aspect of treatment
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Injection mensuelle de buprénorphine à libération prolongée
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Topical nonsteroidal anti-inflammatory drugs
  • Postcoital bleeding
  • Phlegmonous gastritis
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Addiction medicine
    • Family medicine, general practice, primary care
    • Internal medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire